Ascletis Pharma Inc is a renowned pharmaceutical company committed to delivering innovative and high-quality healthcare solutions. The company's core values encompass integrity, collaboration, and patient-centricity. Ascletis Pharma Inc strives to make a positive impact on society by providing breakthrough therapies and improving patient outcomes. With a focus on research and development, Ascletis Pharma Inc aims to address unmet medical needs and bring cutting-edge treatments to individuals worldwide. By upholding these values and embracing a patient-first approach, Ascletis Pharma Inc establishes itself as a trusted leader in the pharmaceutical industry.

Ascletis Pharma Inc is primarily present in China. The company is headquartered in Hangzhou, Zhejiang Province, China. Ascletis Pharma Inc is a leading innovative biotechnology company focused on the research, development, and commercialization of innovative therapies for the treatment of liver diseases and viral infections, with a particular emphasis on hepatitis B. With a strong presence in China, Ascletis Pharma Inc is dedicated to improving patient outcomes and addressing the unmet medical needs in the region.

Ascletis Pharma Inc has achieved several significant milestones. The company has successfully developed and received regulatory approval for a range of innovative drugs, including Ganovo, a direct-acting antiviral for the treatment of chronic hepatitis C. Ascletis Pharma Inc has also established a strong partnership network with renowned global pharmaceutical companies and research institutions. Furthermore, the company has expanded its global presence by entering into licensing agreements and collaborations for the commercialization of its products in various markets worldwide. These accomplishments reflect Ascletis Pharma Inc's commitment to advancing healthcare by delivering breakthrough therapies and driving growth in the pharmaceutical industry.

Ascletis Pharma Inc is a reputable pharmaceutical company with a rich history and background. Founded in 2011, Ascletis Pharma Inc focuses on developing and commercializing innovative drugs for viral hepatitis and other liver diseases. The company has built a strong presence in the global pharmaceutical market through its dedication to research and development. Ascletis Pharma Inc has established itself as a leader in the field of antiviral therapies, with a diverse portfolio of products and a commitment to improving patient outcomes. With its strong track record and commitment to innovation, Ascletis Pharma Inc continues to make significant contributions to the healthcare industry.

The main competitors of Ascletis Pharma Inc in the market are national and multinational pharmaceutical companies that operate in the same therapeutic areas as Ascletis, such as antiviral medications and liver disease treatments. These competitors include Gilead Sciences Inc, AbbVie Inc, Bristol-Myers Squibb Company, and Johnson & Johnson.

Ascletis Pharma Inc is primarily active in the pharmaceutical industry.

Ascletis Pharma Inc is a biopharmaceutical company specializing in the research, development, and commercialization of innovative drugs for the treatment of liver diseases and cancer. As part of its business model, Ascletis Pharma Inc focuses on identifying and acquiring promising drug candidates, conducting clinical trials to evaluate their efficacy and safety, obtaining necessary regulatory approvals, and eventually commercializing the approved drugs in global markets. Through its commitment to breakthrough research and strategic collaborations, Ascletis Pharma Inc aims to address unmet medical needs and improve patient outcomes.

Ascletis Pharma P/E-luku on −3,93.

Ascletis Pharma KUV on 0.

AlleAktien Laatuscore Ascletis Pharma on 3/10.

Liikevaihtoa ei voida tällä hetkellä laskea yritykselle Ascletis Pharma.

odotettu Ascletis Pharma voitto on −233,89 milj. CNY.

The company Ascletis Pharma Inc is an innovative biopharmaceutical company based in China, specializing in the development and marketing of drugs for people with serious and life-threatening diseases such as Hepatitis B, Hepatitis C, HIV/AIDS, and solid tumors. They conduct extensive research and development activities in collaboration with their subsidiaries and joint venture partners. Ascletis is a leading provider of self-developed Category 1 medications, with products available in China and other selected markets. Their main areas of focus are research and development, production, and marketing of pharmaceuticals. They strive to invest regularly in new developments, particularly in researching and developing new medicines for treating serious and life-threatening diseases. The company has achieved recent successes in launching new products for patients with serious illnesses, such as innovative medicines for Hepatitis B, Hepatitis C, and HIV/AIDS. In addition to their core business, Ascletis has also ventured into the development of diagnostic products. Their strategy includes establishing a strong presence in the Chinese market and selected regional markets, as well as pursuing international expansion through collaborations and acquisitions. Overall, Ascletis Pharma Inc is an innovative biopharmaceutical company dedicated to the development and marketing of drugs for the treatment of serious and life-threatening diseases such as Hepatitis B, Hepatitis C, HIV/AIDS, and solid tumors. They conduct extensive research and development activities, and possess a strong production and distribution organization. With their unique combination of scientific expertise and operational efficiency, Ascletis is able to develop and implement innovative solutions in various sectors of the healthcare industry.

Ascletis Pharma maksaa osinkoa 0 CNY, joka jaetaan erässä vuoden aikana.

Osinkoa ei voida tällä hetkellä laskea Ascletis Pharma:lle tai yhtiö ei maksa osinkoa.

Ascletis Pharma:n ISIN on KYG0520K1094.

Ascletis Pharma:n WKN on A2JRKN.

Ascletis Pharma:n tunnus on 1672.HK.

Viimeisen 12 kuukauden aikana Ascletis Pharma maksoi osinkoa edestä. Tämä vastaa noin osinkotuottoa. Seuraavan 12 kuukauden aikana Ascletis Pharma maksanee ennusteiden mukaan 0 CNY osingon.

Ascletis Pharma:n tämänhetkinen osinkotuotto on .

Ascletis Pharma maksaa osinkoa neljännesvuosittain. Osingot jaetaan kuukausina .

Ascletis Pharma maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Seuraavalle 12 kuukaudelle odotetaan 0 CNY suuruisia osinkoja. Tämä vastaa 0 % osinkotuottoa.

Ascletis Pharma kuuluu sektoriin 'Terveys'.

Saadaksesi viimeisimmän Ascletis Pharma osingon 6.7.2024, jonka suuruus on 0 CNY, sinun oli oltava omistanut osakkeen ennen ex-päivää, joka oli 6.7.2024.

Viimeisin osinko maksettiin 6.7.2024.

Vuonna 2023 Ascletis Pharma maksoi 0 CNY osinkoina.

Ascletis Pharma:n osingot maksetaan CNYssa.